Skip to main content
. Author manuscript; available in PMC: 2020 Nov 30.
Published in final edited form as: JAMA Dermatol. 2015 Jan;151(1):23–32. doi: 10.1001/jamadermatol.2014.1550

Table 3.

Reported Cases of Non–Donor Transferred Vitiligo and/or AA Occurring After Allogeneic HSCT

Vitiligo and/or AA
Source, Year Patient Sex/Age, y Donor Sex Disease Transplant Conditioning Condition Time to Occurrencea Distribution Type of Skin GvHD
Nagler et al,13 1996 M/14 NR SAA TLI/Cyc Vitiligo 3 mo Total leukoderma, leukotrichia cGvHD-Lich
Aubin et al,7 2000 M/44 F CML Cyc/Thiotepa/TBI Vitiligo 5 mo Generalized cGvHD-Lich
Au et al,6 2001 M/35 NR CML NR Vitiligo 3 y Generalized, leukotrichia aGvHD grade 4
F/36 NR ALL NR Vitiligo 3–5 y Generalized aGvHD grade 3
Jacobsohn et al,11 2002 M/14 NR CML Bu/Ara-C/TBI Vitiligo 5 mo Total leukoderma, leukotrichia cGvHD-Lich
Sanli et al,19 2004 M/26 NR AML Bu/Cyc AA 6 mo Left parietal, vertex, lateral right eyebrow cGvHD-Lich
M/19b NR CML Bu/Cyc Vitiligo and AA 8 mo Vitiligo: face, neck, trunk, UE/LE; AA: temporal/occipital NR
M/31 NR CML Bu/Cyc AA 3 mo Eyebrows, forearms NR
Cho et al,9 2005 M/15 NR ALL Cyc/TBI Vitiligo 3 mo Generalized aGvHD
M/30 F CML Cyc/TBI Vitiligo 2 y Generalized aGvHD
M/28 F ALL Cyc/TBI Vitiligo 26 mo Generalized cGvHD-Scl
M/43 F MDS Bu/TBI/Cyc Vitiligo 3 mo Face, UE cGvHD
Williams et al,17 2008 M/55 NR MDS NR Vitiligo 3 y Total leukoderma, leukotrichia cGvHD-Epid
M/66 NR MDS RIC Vitiligo 3 y Generalized cGvHD
Cathcart and Marrell,8 2007 M/15 M FA/AML Flu/TBI/Cyc/AT G Vitiligo 4 y Hands, arms, neck, trunk, genitalia aGvHD
Sanli etal,18 2008 M/34 M CML Bu/Cyc Vitiligo 4 y Generalized, leukotrichia cGvHD-Lich
M/19b M CML Bu/Cyc Vitiligo and AA 8 mo AA: temporal, occipital; Vitiligo: face, neck, trunk, UE/LE NR
M/44 F CML Bu/Cyc Vitiligo 7 mo Face, hair, eyelids, trunk, UE/LE cGvHD-Fol
M/44 F CML Bu/Cyc Vitiligo 4 yc Face, dorsum of hands cGvHD-Scl
F/41 M CML Bu/Flu Vitiligo 6 mo Face NR
Heath et al,10 2009 F/2 NR SCID Bu/Cyc/ATG Vitiligo 4 mo Chest, arms, legs, face, scalp aGvHD
M/5 NR X-SCID Bu/Cyc Vitiligo NR Diffuse depigmentation, scattered leukotrichia aGvHD
Lee etal,12 2009 M/23 F SAA Cyc Vitiligo 2 y Face, trunk, UE/LE NR
Tan et al,16 2011 F/48 M MDS Cyc/Bu Vitiligo 5 yd Face, trunk, UE/LE cGvHD-Lich, Scl
Kamińska et al,20 2012 M/38 NR aApAn Flu/Alemtuzumab/Mel AA 6 mo Diffuse alopecia cGvHD
Oh and Lee,15 2013 F/36 NR ALCL NR Vitiligo 3 wk UE/LE, trunks NR
Nambudiri et al,14 2013 M/15 F X-SCID None Vitiligo 1 mo Total leukoderma, leukotrichia cGvHD-Scl

Abbreviations: AA, alopecia areata; aApAn, acquired aplastic anemia; aGvHD, acute graft-vs-host disease; ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; Ara-C, cytarabine; ATG, antithymocyte globulin; Bu, busulfan; cGvHD, chronic graft-vs-host disease; CML, chronic myelogenous leukemia; Cyc, cyclophosphamide; Epid, epidermal; FA, Fanconi anemia; Flu, fludarabine; HSCT, hematopoietic stem cell transplantation; LE, lower extremities; Lich, lichenoid; MDS, myelodysplastic syndrome; Mel, melphalan; NR, not reported; RIC, reduced-intensity conditioning; SAA, severe aplastic anemia; SCID, severe combined immunodeficiency; Scl, sclerotic; TBI, total body irradiation; TLI, total lymph node irradiation; UE, upper extremities; X-SCID, x-linked SCID.

a

Indicates time from allogeneic HSCT to onset of vitiligo or AA.

b

The case by Sanli et al 2008 may represent the same patient as the 19-year-old patient in Sanli et al 2004.

c

The donor (sister) of this patient had generalized vitiligo for 10 y. The authors postulate that the development of vitiligo 4 years after transplant was not likely from passive donor transfer.

d

This patient received 2 allogeneic HSCTs; the time shown refers to time after the second allogeneic HSCT.